- Abstracts are available in the TAT 2015 congress supplement Annals of Oncology. Free to view also to non-subscribers.
- Presentations can be viewed or downloaded in PDF format.
- Watch interviews with faculty members about TAT 2015 and their personal areas of expertise in targeted therapy development.
TAT 2015 was the third TAT congress held in Paris after TAT 2011 and 2013 and the first one organized under the full responsibility of Cancer Institute Gustave Roussy. This year’s meeting was attended by about 450 delegates from 38 countries. They were offered 46 invited lectures and 6 oral abstracts, divided over 11 plenary sessions, and dozens of posters. Absolute highlights were the TAT 2015 Honorary Award Lecture, presented by Professor Hilary Calvert, and the Keynote Lecture by Professor Paul Workman.
The plenary session themes were quite diverse as usual, providing up-to-date overviews and discussion of the most promising targets and targeted agents under development in early phase clinical studies or ready to begin clinical evaluation after successful preclinical development. Novel immunological targets/agents were very well represented in this year’s program with two plenary sessions entirely devoted to this emerging and already quite successful class of agents and treatments. The session on phase 1 studies – ongoing or completed – brought several new, previously unpublished data to the scene. A broad range of promising targeted agents was discussed in dedicated plenary sessions on e.g., CDK-targeting agents, DNA-repair targeting agents, agents having epigenetic targets, in particular BET bromodomain inhibitors, mutant-specific kinase inhibitors in NSCLC, targeting ALK or EGFR tyrosine kinase, and agents targeting cancer cell metabolic dysfunction. The session on novel approaches to evaluating tumor response to molecular targeted agents illustrated the challenges that targeted agents have brought to the stage in the domain of drug development methodology.